Progress Towards the Development of a Universal Influenza Vaccine

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Aug 26

PMID 36016306

Authors

Wen-Chien Wang

Ekramy E Sayedahmed

Suryaprakash Sambhara

Suresh K Mittal

Affiliations

Soon will be listed here.

Abstract

Influenza viruses are responsible for millions of cases globally and significantly threaten public health. Since pandemic and zoonotic influenza viruses have emerged in the last 20 years and some of the viruses have resulted in high mortality in humans, a universal influenza vaccine is needed to provide comprehensive protection against a wide range of influenza viruses. Current seasonal influenza vaccines provide strain-specific protection and are less effective against mismatched strains. The rapid antigenic drift and shift in influenza viruses resulted in time-consuming surveillance and uncertainty in the vaccine protection efficacy. Most recent universal influenza vaccine studies target the conserved antigen domains of the viral surface glycoproteins and internal proteins to provide broader protection. Following the development of advanced vaccine technologies, several innovative strategies and vaccine platforms are being explored to generate robust cross-protective immunity. This review provides the latest progress in the development of universal influenza vaccines.

Citing Articles

Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.

Leong K, Tham S, Poh C Virol J. 2025; 22(1):71.

PMID: 40075519 PMC: 11900334. DOI: 10.1186/s12985-025-02645-6.

Antiviral and Immune Enhancement Effect of in Viral Diseases: A Potential Broad-Spectrum Antiviral Drug.

Gao P, Li X, Ding J, Peng B, Munir M, Liu F Molecules. 2025; 30(4).

PMID: 40005144 PMC: 11858313. DOI: 10.3390/molecules30040831.

Adenoviral Vector-Based Vaccine Expressing Hemagglutinin Stem Region with Autophagy-Inducing Peptide Confers Cross-Protection Against Group 1 and 2 Influenza A Viruses.

Wang W, Sayedahmed E, Alhashimi M, Elkashif A, Gairola V, Murala M Vaccines (Basel). 2025; 13(1).

PMID: 39852874 PMC: 11769558. DOI: 10.3390/vaccines13010095.

Inverted HA-EV immunization elicits stalk-specific influenza immunity and cross-protection in mice.

Zhu W, Dong C, Wei L, Kim J, Wang B Mol Ther. 2025; 33(2):485-498.

PMID: 39741410 PMC: 11852689. DOI: 10.1016/j.ymthe.2024.12.052.

Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen.

Verhoeven D, Sponseller B, Crowe Jr J, Bangaru S, Webby R, Lee B NPJ Vaccines. 2024; 9(1):247.

PMID: 39702334 PMC: 11659547. DOI: 10.1038/s41541-024-01037-1.

References

de Jong J, Beyer W, Palache A, Rimmelzwaan G, Osterhaus A . Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol. 2000; 61(1):94-9. View

Gross P, Ennis F, Gaerlan P, DENSON L, DENNING C, SCHIFFMAN D . A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis. 1977; 136(5):623-32. DOI: 10.1093/infdis/136.5.623. View

Ebrahimi S, Tebianian M . Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes. 2010; 42(1):1-8. DOI: 10.1007/s11262-010-0547-7. View

Bhatnager R, Bhasin M, Arora J, Dang A . Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach. J Biomol Struct Dyn. 2020; 39(15):5690-5705. DOI: 10.1080/07391102.2020.1787227. View

Hause B, Collin E, Liu R, Huang B, Sheng Z, Lu W . Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. mBio. 2014; 5(2):e00031-14. PMC: 3958797. DOI: 10.1128/mBio.00031-14. View

Yan J, Morrow M, Chu J, Racine T, Reed C, Khan A . Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine. 2017; 36(22):3079-3089. DOI: 10.1016/j.vaccine.2017.09.086. View

Carter N, Curran M . Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011; 71(12):1591-622. DOI: 10.2165/11206860-000000000-00000. View

Kolpe A, Schepens B, Fiers W, Saelens X . M2-based influenza vaccines: recent advances and clinical potential. Expert Rev Vaccines. 2016; 16(2):123-136. DOI: 10.1080/14760584.2017.1240041. View

Lee Y, Kim M, Lee Y, Kim Y, Kang S . Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines. Immune Netw. 2015; 15(5):213-21. PMC: 4637342. DOI: 10.4110/in.2015.15.5.213. View

10.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

11.

Van Kampen K, Shi Z, Gao P, Zhang J, Foster K, Chen D . Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2004; 23(8):1029-36. DOI: 10.1016/j.vaccine.2004.07.043. View

12.

Assarsson E, Bui H, Sidney J, Zhang Q, Glenn J, Oseroff C . Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol. 2008; 82(24):12241-51. PMC: 2593359. DOI: 10.1128/JVI.01563-08. View

13.

Nachbagauer R, Feser J, Naficy A, Bernstein D, Guptill J, Walter E . A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2020; 27(1):106-114. DOI: 10.1038/s41591-020-1118-7. View

14.

Schwartzman L, Cathcart A, Pujanauski L, Qi L, Kash J, Taubenberger J . An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. mBio. 2015; 6(4):e01044. PMC: 4513078. DOI: 10.1128/mBio.01044-15. View

15.

Jegerlehner A, Schmitz N, Storni T, Bachmann M . Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172(9):5598-605. DOI: 10.4049/jimmunol.172.9.5598. View

16.

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A . Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012; 4(115):115ra1. PMC: 3627207. DOI: 10.1126/scitranslmed.3003155. View

17.

Dhakal S, Renu S, Ghimire S, Lakshmanappa Y, Hogshead B, Feliciano-Ruiz N . Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs. Front Immunol. 2018; 9:934. PMC: 5940749. DOI: 10.3389/fimmu.2018.00934. View

18.

Igyarto B, Jacobsen S, Ndeupen S . Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr Opin Virol. 2021; 48:65-72. PMC: 8065267. DOI: 10.1016/j.coviro.2021.03.008. View

19.

Cianci C, Gerritz S, Deminie C, Krystal M . Influenza nucleoprotein: promising target for antiviral chemotherapy. Antivir Chem Chemother. 2012; 23(3):77-91. DOI: 10.3851/IMP2235. View

20.

Wilkinson T, Li C, Chui C, Huang A, Perkins M, Liebner J . Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012; 18(2):274-80. DOI: 10.1038/nm.2612. View